Hypothesis

Enlarged hydroxyapatite (HA) crystals in aged bone sequester undercarboxylated osteocalcin (ucOC), preventing its recycling by vitamin K–dependent γ‑carboxylation and impairing osteocyte mechanosensing. This creates a self‑reinforcing loop: trapped ucOC reduces HA‑binding competence of osteocalcin, further diminishing mineralization regulation, while altered HA size modifies pericellular fluid flow, lowering shear stress on osteocytes and increasing sclerostin expression.

Mechanistic Rationale

1. Cryo‑EM shows VKGC carboxylates osteocalcin in a strict order; low vitamin K yields mono‑ or di‑carboxylated forms that have reduced affinity for HA.
2. Larger HA crystals present a lower surface‑to‑volume ratio and altered charge distribution, creating nucleation sites that can adsorb ucOC via electrostatic interactions.
3. Osteoclast‑mediated decarboxylation releases OC into the resorption lacuna; ucOC that remains bound to HA is inaccessible to circulating vitamin K2, blocking reconversion.
4. Accumulated ucOC in the matrix competes with carboxylated OC for HA binding sites, weakening the feedback that normally limits crystal growth.
5. Changes in HA size and matrix composition alter interstitial fluid dynamics, reducing the fluid shear stress sensed by osteocyte processes; low shear stress upregulates sclerostin, suppressing Wnt‑driven bone formation.
6. Elevated sclerostin further decreases osteoblast activity, perpetuating low vitamin K recycling and ucOC accumulation.

Predictions

• In vitamin K‑insufficient aged mice, histomorphometry will show higher ucOC colocalization with enlarged HA crystals compared with young controls.
• Blocking HA‑ucOC interaction (e.g., with a synthetic peptide mimicking the OC HA‑binding motif) will reduce ucOC matrix retention, increase circulating carboxylated OC, and lower sclerostin levels.
• Combined vitamin K2 supplementation and low‑intensity vibration will normalize HA crystal size, decrease matrix ucOC, restore osteocyte shear stress signaling, and improve bone formation rates more than either intervention alone.
• Direct measurement of pericellular fluid flow using microfluidic bone‑on‑chip models will reveal reduced shear stress in matrices with large HA crystals and high ucOC, which is rescued by peptide disruption of HA‑ucOC binding.

Experimental Approach

Animals: 24‑month‑old C57BL/6 mice fed a vitamin K‑deficient diet; age‑matched young controls on normal diet. Interventions: (i) vehicle, (ii) vitamin K2 (MK‑7) 45 µg/kg/day, (iii) low‑intensity vibration (0.3 g, 30 Hz, 15 min/day), (iv) vitamin K2 + vibration, (v) HA‑binding peptide (1 mg/kg) alone or with vitamin K2. Endpoints (after 8 weeks):

• HA crystal size and distribution by synchrotron‑based X‑ray diffraction and transmission electron microscopy.
• ucOC and carboxylated OC levels in bone extracts and serum by ELISA with isoform‑specific antibodies.
• Immunohistochemistry for ucOC colocalization with HA (using fluorescently labeled HA‑binding peptide) and for sclerostin in osteocytes.
• Osteocyte apoptosis (TUNEL) and dendritic connectivity (confocal imaging of Cx43).
• In vivo bone formation rates via double‑label fluorochrome histomorphometry.
• Ex vivo bone‑on‑chip assays: murine tibial segments perfused with fluorescent microspheres; particle image velocimetry to quantify shear stress around osteocyte lacunae. Statistical analysis: Two‑way ANOVA with factors treatment and age; post‑hoc Tukey; significance set at p<0.05. Power analysis indicates n=10 per group to detect a 20 % change in ucOC/HA colocalization (α=0.05, β=0.2).

If the peptide reduces matrix ucOC and rescues osteocyte signaling despite vitamin K deficiency, the hypothesis is supported. If ucOC remains bound and sclerostin stays high regardless of intervention, the hypothesis is falsified.